ODYY - Odyssey Health Inc. (ODYY) Moving to Fill Gaps in Treatment and Management of Concussion Among Military Service Members
- Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion
- Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concussion”
- Although concussion greatly impacts the military, there are significant gaps in the understanding of the optimal diagnostic, treatment, and management criteria
- Odyssey is looking to bridge this informational gap with its clinical trial and intends to start its U.S. Phase II trials at military training sites, subject to the FDA’s approval of the results of its Phase I study
The Center for Disease Control (“CDC”) notes that more than 430,000 U.S. service members were diagnosed with a traumatic brain injury (“TBI”) between 2000 and 2020 (https://ibn.fm/6Yycd), with 75-83% of all these cases being mild (“mTBI”), according to different studies (https://ibn.fm/0MQas). These statistics make mTBI, also known as concussion, the most common TBI affecting military personnel. But despite its prevalence, mTBI is the least understood and most difficult to diagnose of the different forms of TBI and has been a largely unexplored area of medical intervention until very recently.
In military settings, head injuries caused by shock waves from explosives, violent impact, or ballistic penetration are cited as the main causes of TBI, with most concussions resulting from blunt trauma. While symptoms from a concussion are “usually self-limited and resolve spontaneously over a...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.